These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 9495454)

  • 1. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
    Vanhoefer U; Voigt W; Hilger RA; Yin MB; Harstrick A; Seeber S; Rustum YM
    Oncol Res; 1997; 9(9):485-94. PubMed ID: 9495454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines.
    Voigt W; Vanhoefer U; Yin MB; Minderman H; Schmoll HJ; Rustum YM
    Anticancer Res; 1997; 17(5A):3707-11. PubMed ID: 9413228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
    Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
    Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity.
    Yoshinari T; Matsumoto M; Arakawa H; Okada H; Noguchi K; Suda H; Okura A; Nishimura S
    Cancer Res; 1995 Mar; 55(6):1310-5. PubMed ID: 7882328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.
    Komatani H; Kotani H; Hara Y; Nakagawa R; Matsumoto M; Arakawa H; Nishimura S
    Cancer Res; 2001 Apr; 61(7):2827-32. PubMed ID: 11306452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy- 13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole- 5,7(6H)-dione (NB-506): its potent antitumor activities in mice.
    Arakawa H; Iguchi T; Morita M; Yoshinari T; Kojiri K; Suda H; Okura A; Nishimura S
    Cancer Res; 1995 Mar; 55(6):1316-20. PubMed ID: 7882329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
    Urasaki Y; Laco G; Takebayashi Y; Bailly C; Kohlhagen G; Pommier Y
    Cancer Res; 2001 Jan; 61(2):504-8. PubMed ID: 11212241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I.
    Yoshinari T; Ohkubo M; Fukasawa K; Egashira S; Hara Y; Matsumoto M; Nakai K; Arakawa H; Morishima H; Nishimura S
    Cancer Res; 1999 Sep; 59(17):4271-5. PubMed ID: 10485471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
    Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB.
    Kanzawa F; Nishio K; Kubota N; Saijo N
    Cancer Res; 1995 Jul; 55(13):2806-13. PubMed ID: 7796407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
    Fukuda M; Nishio K; Kanzawa F; Ogasawara H; Ishida T; Arioka H; Bojanowski K; Oka M; Saijo N
    Cancer Res; 1996 Feb; 56(4):789-93. PubMed ID: 8631015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506.
    Ohkubo M; Kojiri K; Kondo H; Tanaka S; Kawamoto H; Nishimura T; Nishimura I; Yoshinari T; Arakawa H; Suda H; Morishima H; Nishimura S
    Bioorg Med Chem Lett; 1999 May; 9(9):1219-24. PubMed ID: 10340602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in rats and dogs: pharmacokinetics, isolation, identification, and quantification of metabolites.
    Takenaga N; Ishii M; Nakajima S; Hasegawa T; Iwasa R; Ishizaki H; Kamei T
    Drug Metab Dispos; 1999 Feb; 27(2):205-12. PubMed ID: 9929504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degradation of topoisomerase I induced by topoisomerase I inhibitors is dependent on inhibitor structure but independent of cell death.
    Fu Q; Kim SW; Chen HX; Grill S; Cheng YC
    Mol Pharmacol; 1999 Apr; 55(4):677-83. PubMed ID: 10101025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo+ ++[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), in mice, rats, dogs, and humans.
    Takenaga N; Hasegawa T; Ishii M; Ishizaki H; Hata S; Kamei T
    Drug Metab Dispos; 1999 Feb; 27(2):213-20. PubMed ID: 9929505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA binding and topoisomerase I poisoning activities of novel disaccharide indolocarbazoles.
    Facompre M; Carrasco C; Colson P; Houssier C; Chisholm JD; Van Vranken DL; Bailly C
    Mol Pharmacol; 2002 Nov; 62(5):1215-27. PubMed ID: 12391286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbamoylation of glutathione reductase by N,N-bis(2-chloroethyl)-N- nitrosourea associated with inhibition of multidrug resistance protein (MRP) function.
    Vanhoefer U; Yin MB; Harstrick A; Seeber S; Rustum YM
    Biochem Pharmacol; 1997 Mar; 53(6):801-9. PubMed ID: 9113101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-edged sword of chemosensitizer: increase of multidrug resistance protein (MRP) in leukemic cells by an MRP inhibitor probenecid.
    Kim HS; Min YD; Choi CH
    Biochem Biophys Res Commun; 2001 Apr; 283(1):64-71. PubMed ID: 11322768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
    Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
    Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypersensitivity of NIH3T3 cells transformed by H-ras gene to DNA-topoisomerase-I inhibitors.
    Ohira T; Nishio K; Kanzawa F; Ishida T; Ohe Y; Arioka H; Funayama Y; Ogasawara H; Kato H; Saijo N
    Int J Cancer; 1996 Sep; 67(5):702-8. PubMed ID: 8782662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.